Generation of AMPKβ1 mutant mice
To investigate the biologic roles of the AMPK β1 subunit, we generated mutant mice using ES cells in which the β1 gene was interrupted by the insertion of a βgeo cassette (henceforth called β1−/− mice). The insertion created a β1-βgeo fusion protein containing exons 1–5 of β1. This produces a mutant β1 protein lacking the terminal 46 amino acids (
Fig. S1A). This deleted domain is required for generation of the active AMPK heterotrimer through interactions with both α and γ subunits and is highly conserved in the closely related AMPK β2 protein (
Iseli et al., 2005). We confirmed the existence of a single βgeo integrant at the predicted site in the β1 locus by Southern blot analysis, PCR genotyping, RT-PCR analysis and nucleotide sequencing (
Fig. S1B-D). We detected the β1-βgeo fusion protein by immunoblotting with a β-gal antibody in lysates from multiple tissues, including brain (
Fig. S1E). The absence of wildtype β1 in lysates from β1-deficient E14.5 telencephalon (forebrain), P7 cerebellum () and MEFs (
Fig. S1F) was confirmed using a β1/β2 C-terminal specific antibody. The loss of β1 caused a significant reduction of activated AMPK (phospho-AMPKα
Thr172) and phosphorylated ACC (phospho-ACC
Ser79), a downstream target of AMPK, in the brain and other organs (,
S1G, H, I, data not shown). A similar reduction in AMPK activity was observed by monitoring phosphorylation of the AMPK artificial substrate (SAMS peptide) (data not shown).
AMPK β1−/− mice display structural and functional brain abnormalities
The β1−/− mutant mice were born in a proper Mendellian ratio, but failed to gain weight normally and were clearly emaciated by postnatal day 14 (P14) (
Fig S2 and
Movie1). They displayed severe tremors, ataxic gait and seizure-like activity and died by P21. Most notably, an examination of P14 β1−/− animals revealed a 50% reduction in overall brain size with severe cerebellar atrophy and marked reduction of the cerebral cortex resulting in improper cortical fusion and exposure of the superior (SC) and inferior colliculi (IC) (;
S3A). A histological examination revealed a nearly complete loss of the dentate gyrus (). The cerebellum was characterized by loss of the inner granule cell layer (IGL), extensive spongiform vacuolation, and disordered laminar organization (). We did not observe abnormalities in brain structure or behavior in β1+/− animals.
To further characterize the extent of neuronal loss, we used the NeuN antibody to perform immunohistochemistry on brain sections. Significant losses (between 35–65%) of cortical neurons and granule neurons of the dentate gyrus () and IGL of the cerebellum were clearly evident in the β1−/− brain (). MAP2 immunohistochemistry and Bielschowsky’s silver staining demonstrated widespread losses of dendritic processes () and white matter axonal projections in these mutant mice (), suggesting that absence of β1 causes loss of neurons and neuronal processes.
To investigate the effects of β1 loss on CNS glia, we examined oligodendrocytes by immunohistochemistry using the Adenomatous Polyposis Coli (APC) antibody and found a 75–80% loss of oligodendrocytes at P14 (;
S3B). This loss caused severe hypomyelination throughout the brain that was particularly evident in the corpus callosum and striatum (,
Fig S3C). Consistent with the deficit in oligodendrocytes, the β1−/− optic nerve was translucent and ~30% thinner than wildtype nerve (
Fig. S3D). Electron microscopic analysis demonstrated severe hypomyelination of mutant P14 optic nerve axons ().
Astrocyte maturation occurs later in development and was difficult to study due to the early lethality of the β1−/− animals. We performed immunohistochemistry on P14 brains using antibodies to GFAP, an intermediary filament enriched in differentiated astrocytes (
Cahoy et al., 2008) and BLBP (brain lipid binding protein), which is expressed in neural progenitors, radial glia and immature/differentiating astrocytes (
Domowicz et al., 2008; Hagedus et al., 2008). The results showed that in addition to extensive astrogliosis in β1−/− mice, there were an increased number of astrocytes throughout the brain (;
S4A,). Moreover, astrocytes in P14 dentate gyrus of wildtype animals expressed low levels of GFAP along with BLBP, whereas astrocytes in β1−/− mice expressed similar levels of BLBP but higher levels of GFAP (
Fig. S4B). At E18.5, consistent with previous findings (
Barnabe-Heider et al., 2005), very few GFAP
+ cells were observed in wildtype mice; however β1−/− brain contained many GFAP
+ migrating astrocytes (), suggesting premature astrocytic differentiation of glial precursors in these mice. Together, these results suggest that while loss of the AMPKβ1 resulted in fewer neurons and oligodendrocytes, this was accompanied by an increased number of fully differentiated astrocytes.
AMPK directed GABA(B) receptor phosphorylation is reduced in seizure-prone β1−/− mice
The extensive brain hypomyelination in β1−/− mice along with their notable tremor and abnormal behavior prompted us to monitor them for seizure activity. Electroencephalogram recordings revealed spontaneous electrographic seizures in mutant animals that usually recurred within less than 10 min (). The seizures in these mice could result from the paucity of oligodendrocytes and resulting decreased in myelinated CNS fibers, the severe brain malformations, abnormal energy homeostasis in the brain, or perhaps through decreased inhibitory neuron activity.
GABA is the major inhibitory neurotransmitter in mammalian brain and it exerts its slow, prolonged effects via the GABA
B receptor, which is made up of two subunits R1 and R2. Interestingly, phosphorylation of the R2 subunit by AMPK at Ser
783, acts to stabilize GABA
B activation of inwardly rectifying K
+ channels and decrease synaptic activity (
Kuramoto et al., 2007). Disturbances of GABA
+ neurons, either through selective loss of these neurons or via hypophosphorylation of the GABA
B R2 receptor, could facilitate seizure propensity. Immunohistochemistry of P14 brain showed that the loss of GABAergic neurons was similar (~ 40%) to the loss of total neurons in β1−/− P14 brain (not shown). However, immunohistochemical as well as western blot analysis using a GABA
B-R2 pSer783-specific antibody revealed that the R2 receptor was hypophosphorylated in β1−/− brain (). Together, these results suggest that loss of AMPK activity could interfere with proper GABAergic signaling, potentially contributing to abnormal electrical activity in the β1−/−postnatal brain.
AMPKβ1−/− NPCs show defective proliferation, differentiation and unregulated apoptosis in vivo
The deficits in multiple cell lineages in the brain suggested that developmental processes were adversely affected by β1 deficiency. We examined mice at a number of embryonic and perinatal ages and found that E18.5 β1−/− embryos were similar in body size to wildtype embryos; however, the β1−/− brain was ~50% smaller (
Fig. S5A–D). To determine whether the decreased size and cell number were due to abnormalities in proliferation and/or apoptosis, we first counted the number of cycling cells using Ki67 immunohistochemistry. We found 22.22 ± 4.66% less Ki67-positive cells around the lateral ventricles in β1−/− brain (). To investigate this cell cycle defect, we pulse-labeled β1−/− E14.5 embryos with BrdU for 1 hr and performed immunohistochemistry with antibodies against BrdU, which marks cells in S-phase, phistone H3 (PH3), which detects cells in M-phase, and Ki67, which detects all actively cycling cells. We observed a similar labeling index (proportion of cells in S-phase [(BrdU
+)/total cycling cells (Ki67
+)] in wildtype and β1−/− forebrain (wt: 32.83 ± 6.66 vs. β1−/−:33.46 ± 4.25) (). However, the number of cells in mitosis (PH3
+ cells) in mutant E14.5 forebrain (), as well as in P7 dentate gyrus and cerebellum (
Fig. S5E–G) were significantly reduced, suggesting that the cell cycle defect occurs after DNA synthesis.
Increased apoptosis could also be responsible for the decreased numbers of neurons and glia and often occurs in response to abnormalities in cell cycle progression. We found large numbers of apoptotic cells by cleaved Caspase3 immunohistochemistry in β1−/− E14.5 forebrain () and P7 cerebellum (
Fig. S5H). Although a few apoptotic cells were present in the proliferative Sox2-positive ventricular zone, the majority were found in the Nestin-positive subventricular zone, particularly in the intermediate zone and subplate of the mutant forebrain (). Double immunolabeling with BrdU and cleaved Caspase 3 antibodies confirmed that the majority of apoptotic β1−/− NPCs reside outside the BrdU positive zone (). As cells that aberrantly exit cell cycle often undergo apoptosis, we examined cell cycle exit of β1−/− NPCs. E14.5 embryos were labeled with BrdU for 24 hr and double immunolabeling with BrdU and Ki67 antibodies was performed. The fraction of BrdU positive cells that were Ki67 negative represents the cells that exited cell cycle during the labeling period. Although, it appeared that a higher number of BrdU positive cells were present outside the subventricular zone in the β1−/− brains (), the majority of these cell were Ki67-negative but cleaved Caspase 3 positive (), suggesting that a defect after S phase is responsible for the massive apoptosis of β1−/− NPCs. Moreover, we found increased numbers of apoptotic Tuj1-positive immature neurons and Olig2-positive oligodendrocyte precursors, indicating thatβ1−/− neural precursors undergo apoptosis as they migrate and differentiate into neurons and oligodendrocytes (). In contrast, no cell death was observed in the astrocyte population at P7 () or at E18.5 (data not shown).
Although the normal body size of β1−/− embryos suggested that there were minimal cell losses in other tissues, the ubiquitous expression of AMPK prompted us to examine whether defects in proliferation and apoptosis could be detected in other regions of the body. We performed pHistone H3 and cleaved Caspase3 immunohistochemistry on sections of E14.5 embryo body, liver and interdigital junctions. Unlike β1−/− embryonic brain, the number of proliferating and apoptotic cells in these β1−/− tissues was similar to wildtype embryo tissues (
Fig. S6A–D). Collectively, these results suggest that loss of the AMPKβ1 subunit leads to proliferative defects and unregulated apoptosis specifically in the progenitors of the developing brain.
Defects in AMPKβ1−/− NPCs are cell autonomous
AMPK is involved in central energy metabolism and the developing brain is sensitive to metabolic imbalances, thus it was important to determine whether the brain anomalies in the β1−/− animals were due to global metabolic abnormalities or whether they were cell autonomous to neural progenitor cells. While global metabolic problems would likely cause deficits in multiple tissues, to clearly address this issue, we isolated mouse embryonic fibroblasts and cultured neurospheres from E12.5 telencephalon from β1−/− and wildtype embryos. In response to energy deprivation, AMPK increases mitochondrial respiration and glucose transporter expression. We examined both glucose transporter expression and basal as well as maximal oxygen consumption and found that they were similar in β1−/− and wildtype NPCs and MEFs (
Fig. S7A–C).
To investigate whether the proliferation and apoptosis defects observed in β1−/− NPCs in vivo were cell-autonomous, we cultured neurospheres and found that β1−/− neurospheres were significantly smaller in diameter (,
S7D) and produced fewer numbers of secondary and tertiary neurospheres (
Fig. S7E). Direct cell counting revealed that growth and self renewal capacity of β1−/− NPCs was severely impaired (). The proliferative rate of β1−/− NPCs was examined using a CFSE washout experiment (see methods for details). Flow cytometric analysis of mean fluorescence intensities of CFSE-labeled cells at 0 and 96 hr revealed that β1−/− NPCs proliferate at about half the rate of wildtype NPCs (). We also used propidium iodide (PI) staining to evaluate the extent of cell death in these cultured neurospheres and found that an increased number of β1−/− NPCs were PI-positive (wt: 23.87 ± 3..33% vs. ± β1−/−: 50.95 ± 7.55%) (), indicating that cell intrinsic defects lead to the abnormalities observed in these mutant NPCs.
To gain insight into how β1-deficiency causes the differential loss of specific CNS cell types, the multilineage differentiation potential of these neurospheres was examined. The β1−/−neurospheres produced fewer Tuj1-positive neurons (55.0 ± 8.25%) and O4-positive oligodendrocytes (60.45 ± 2.5%) but similar numbers of GFAP-positive astrocytes (;
S8A–C). However, β1−/− astrocyte differentiation was not normal. Immunocytochemistry with antibodies to BLBP (immature astrocyte marker), GFAP and Aquaporin4 (mature astrocyte markers) (
Bachoo et al., 2004;
Cahoy et al., 2008), showed that an increased number of β1−/−astrocytes lost BLBP expression and displayed robust GFAP and Aquaporin4 expression (
Fig. S8D–G), indicating that they prematurely differentiate in vitro as they do in vivo.
Finally, the severe cerebellar defects in β1−/− animals prompted us to examine cultured cerebellar granule cell precursors from P2 animals. We found that reaggregate formation as well as neurite projection was severely impaired in the β1−/− precursors (
Fig. S9A). We also observed that 60–70% of NeuN
+ β1−/− reaggregates were apoptotic (
Fig. S9B, C). In sum, these results indicate that cell autonomous defects caused by β1-deficiency result in aberrant proliferation and/or cell fate determination of neural precursors.
AMPK β subunits play functionally distinct roles in NPCs
The abnormalities in β1−/− NPCs are caused by cell intrinsic mechanisms rather than by an altered global metabolic state in these mutant mice. To understand why β1 deficiency results in such devastating NPC defects, we performed western blot analysis on β1−/− neurospheres and found that pAMPK was almost absent, while pACC (a canonical target of AMPK) was reduced by ~50% (). The low AMPK activity in NPCs prompted us to further investigate why the highly related AMPKβ2 subunit cannot complement the β1 mutation in these cells. We examined their expression and subcellular localization using an antibody that recognizes the C-terminus of both β subunits and found that β1 is expressed at a 6–8-fold higher level than β2 in wildtype NPCs (
Fig. S10A). While β2 expression in β1−/− NPCs was increased (
Fig. S10A), it was obviously insufficient to compensate for loss of β1 function. Subcellular fractionation studies showed that active AMPK was reduced in both the cytoplasmic and nuclear fractions of β1−/− NPCs (
Fig. S10B). Interestingly, immunocytochemistry using β1- or β2-N-terminal specific antibodies (
Fig. S10C) as well as Western blot assays using the common β1/β2-C-terminal specific antibody showed that β1 was distributed throughout the cell, whereas the β2 subunit was primarily cytoplasmic (
Fig. S10D,E). Moreover, in wildtype NPCs, immunoprecipitated AMPK complexes captured with AMPKα1/2 antibody contained significantly more β1 that β2 (
Fig. S10F, G). Interestingly, the absence of the β1 subunit in NPCs resulted in lower levels of α subunits, presumably reflecting decreased stability of the catalytic subunits in cells lacking β1 (
Fig. S10B).
The widespread cellular distribution of the β1 subunit, particularly in the nucleus, may imbue it with functions that are not shared by β2. Expression of His-tagged human β1 or β2 by lentivirus (
Fig. S10H) demonstrated that re-introduction of β1 rescued the growth (), self renewal (), and apoptosis (;
S10I) defects of β1−/− NPCs, whereas the β2 subunit had no effect. To definitively prove that AMPK activity is necessary for regulated proliferation of NPCs, we expressed constitutively active (ca) and dominant negative (dn) AMPKα2 mutants in β1−/− and wildtype NPCs. We found that while caAMPK partially rescued the self renewal and apoptosis defects of β1−/− NPCs, dnAMPK severely reduced self renewal and caused catastrophic death of wildtype NPCs (). These results indicate that AMPK is a crucial regulator of NPC growth and that its activity is uniquely dependent on the β1 subunit in NPCs.
AMPK directly phosphorylates Rb to regulate NPC cell cycle
The cell autonomous defects in NPC growth caused by loss of β1 prompted us to investigate the MAP kinase (Erk1/2) and PI3 kinase signaling (Akt) pathways, which are crucial for NPC proliferation, survival and differentiation. However we found these pathways were normal in β1−/− NPCs (
Fig. S11A, B), suggesting that abnormalities in other effectors are responsible for the deficits in β1−/− NPCs. Other molecules central to NPC health, such as GSK3β, which phosphorylates and destabilizes N-Myc (transcription factor for D-type cyclins) (
Galderisi et al., 2003;
Kenney et al., 2004), N-Myc, cyclin D1 and D2, and the cell cycle inhibitors p16, p18, p21 and p27 were all expressed at normal levels in β1−/− NPCs (
Fig. S11C, D). Another critical regulator of cell growth is p53, which is phosphorylated at Ser
15 by AMPK (
Jones et al., 2005) was also unaltered in β1−/− NPCs (
Fig. S11D). Collectively, these data suggest that other effectors or cell cycle regulators downstream of the cyclins and cell cycle inhibitors must account for the β1−/− NPC deficits.
Despite the seeming normalcy of most cell cycle regulators in β1−/− NPCs, the striking resemblance of the brain abnormalities in β1-deficient mice with those observed in animals lacking N-Myc (
Knoepfler et al., 2002), cyclin D1/D2 (
Ciemeryc et al., 2002), Rb (
Lee et al., 1992) and Rb family proteins (
McLear et al., 2006) prompted us to examine the cyclin downstream target Rb. Rb is exquisitely regulated by multiple phosphorylation events and we noticed in searching the Phosphosite database (
www.phosphosite.org) that one of the multiple Rb phosphorylation sites, Ser
804 (Ser
811 in human), resembled the AMPK consensus phosphorylation site (). Immunoblot analysis using antibodies specific for Rb phosphoSer
804 and pan Rb antibodies revealed that phosphorylation of Ser
804 is greatly decreased in β1−/− NPCs (). No change in total Rb or in phosphorylation at another site (Ser
780) was observed, suggesting that Ser
804 is specifically hypophosphorylated in β1−/− NPCs. The antibody used in our study recognizes both Ser
800 and Ser
804. However, since only the Ser
804 and not the Ser
800 conforms to the AMPK consensus site, we believe that Ser
804 is the likely residue phosphorylated by AMPK and will be used in the text henceforth. Our mutagenesis studies (see later) further reinforce this view.
The CDK-Cyclin D complex is known to phosphorylate Rb at Ser804, thus the hypophosphorylation at this site in β1−/− NPCs could result from an indirect effect on CDK4/6 activity or a direct effect of AMPK on Rb. CDK4/6, which exist in complexes with cyclinD1/D2, were immunoprecipitated using cyclin D1/2 antibodies and the activity was measured by nonradioactive in vitro kinase assays using bacterially produced Rb fusion protein (residues 701–928) as the substrate. We found that CDK4/6 activity from β1−/− and wildtype NPCs was equivalent (), indicating that β1-deficiency did not affect CDK activity. To test whether AMPK directly phosphorylates Rb, we immunoprecipitated the AMPK holoenzyme (α/β/γ heterotrimers) using anti-AMPKα1/2 antibody from wildtype NPCs. In vitro kinase assays using this immunoprecipitated AMPK enzyme (or cyclin/CDK4/6 complex, control), and the Rb protein mentioned above, showed that AMPK directly phosphorylated Rb at Ser804 and that this modification could be inhibited by the AMPK inhibitor, compound C ().
In proliferating cells, growth factor signaling promotes CDK-dependent phosphorylation of Rb to inhibit it from sequestering the E2F transcription factors. As a consequence of the high level of hypophosphorylated Rb in β1−/− NPCs, the amount of E2F1 sequestered by Rb should be higher in these cells. Rb was immunoprecipitated from wildtype and mutant NPCs, and Western analysis using anti-E2F1 antibody showed significantly more Rb-E2F1 complexes in β1−/− NPCs (), suggesting that aberrant regulation of the Rb-E2F1 complex is at least partially responsible for the β1−/− NPC deficiencies.
β1−/− NPCs display defects in the G2M phase of the cell cycle
The Rb-E2F complex plays multiple cellular roles including serving as a gate keeper of the G1-S restriction point, the G2-M phase, cell cycle exit, cellular differentiation, and regulation of apoptotic cell death (
Burkhart and Sage, 2008;
Rigberg et al., 1999;
Naderi et al., 2002;
Yen and Sturgill 1998;
Niculescu et al., 1998). Many of these defects are present in β1−/− NPCs and our previous analysis demonstrated alterations in cell proliferation. The abnormal regulation of Rb in these cells prompted us to perform flow cytometric analysis to examine cell cycle progression in these cells. In comparing β1−/− and wildtype NPCs, we found comparable numbers of cells in S phase (wt: 16.47 ± 4.7%; β1−/−: 18.06 ± 3.95%), less β1−/− cells in G1 (wt: 71.5 ± 6.5%; β1−/−: 58.25 ± 3.25%, p = 0.005), and almost twice as many β1−/− cells in G2M phase (wt: 12.12 ± 1.7%; β1−/−: 22.56 ± 1.95%, p = 0.001) (
Fig S12–13), indicating that β1−/− cells have defects that prevent them properly exiting or re-entering the cell cycle.
To firmly establish a direct connection between these cell cycle defects and the AMPK-Rb signaling axis, we examined the levels of pAMPK and pRb in β1−/− NPCs expressing β1, β2, caAMPK or dnAMPK. β1−/− NPCs expressing caAMPK or β1, but not β2, showed increased levels of pAMPK, pRb and pACC levels (
Fig. S14 A–D), while wildtype NPCs expressing dnAMPK showed significantly decreased Rb and ACC phosphorylation (
Fig. S14 C, D). Together, these results indicate the importance of the AMPK–Rb signaling axis in NPC growth, a pathway that is largely regulated through the β1 subunit.
The highly orchestrated, cyclical phosphorylation of Rb throughout the cell cycle makes Rb overexpression studies difficult. Nevertheless, we generated lentiviruses expressing wildtype Rb, Rb(S804A), removing the critical phosphorylation site, and Rb(S804E) and Rb(S804D), potentially creating phophomimetics. These lentiviruses were used to examine whether an Rb phosphomimetic mutant could rescue the β1−/− NPC growth defect, and whether a phosphorylation-resistant Rb would cause growth defects in wildtype NPCs. We infected wildtype NPCs with lentivirus expressing GFP (control), wildtype Rb or Rb(S804A) and β1−/−NPCs with lentivirus expressing GFP (control), wildtype Rb, Rb(S804A), or Rb(S804E), Rb(S804D). The cells were counted 24 hr after infection. Both wildtype Rb and Rb(S804A) caused significant growth reduction in wildtype NPCs. β1−/− NPCs expressing GFP, wildtype Rb or Rb(S804A) showed poor growth; however, those expressing the phophomimetic mutants, showed improved growth (). We continued to observe these cells and found that by 48 hr the neurospheres expressing Rb(S804E) or Rb(S804D) stopped growing and began to look unhealthy, suggesting that constitutive phosphorylation of Rb at this site may prevent cells from re-entering cell cycle.
Previous analysis showed that β1−/− NPC cell cycle progression was blocked at the G2M phase. We therefore investigated whether β1−/− NPCs expressing Rb(S804E) or Rb(S804D) could now transit the G2M stage. Flow cytometric analysis performed on cells 24 hr after lentiviral infection showed that β1−/− NPCs expressing wildtype Rb or Rb(S804A) had 27% cells in G2M, whereas β1−/− NPCs expressing Rb(S804E) or Rb(S804D) had 16% cells in G2M (,
S15–19). Interestingly, wildtype NPCs expressing Rb(S804A) had more cells (~22%) in G2M than those expressing GFP (~10%) (,
S20–21). These results indicate that the hypophosphorylation of Rb at Ser
804 is responsible for the G2M defect in β1−/− NPCs, as a phosphomimetic RB mutant can partially restore the ability of these cells to transit G2M. It is interesting that although Rb is phosphorylated at 19 different Ser/Thr residues, many of which could serve overlapping as well as specific functions, the phosphorylation of Rb at Ser
804 appears to play an important role in G2M phase and/or cell cycle exit in NPCs.
Stem cell growth factors as well as metabolic perturbations activate AMPK to promote NPC proliferation
We extended our studies to explore whether wildtype NPC growth was enhanced by activation of AMPK via genetic or physiological stimuli. Constitutively active AMPK not only enhanced proliferation of wildtype NPCs (), but also caused a significant increase in Rb phosphorylation (). Accordingly, the proportion of E2F1 sequestered by Rb was reduced in wildtype NPCs expressing caAMPK, where as dnAMPK caused significantly more E2F1 sequestration (). It is intriguing that overexpression of the β1 but not β2 subunit caused a distinct increase in wildtype NPC growth (; 6I), supporting its role in regulating AMPK-mediated NPC proliferation.
The effects of AMPKβ1 deletion on Rb phosphorylation led us to consider whether the highly conserved AMPK signaling pathway is fundamentally important for NPC responses to proliferative signals such as growth factors. We cultured wildtype NPCs in the absence of growth factors for 2 hr (withdrawal phase) and then added back EGF and FGF for 1 hr. Cells treated with growth factors had increased levels of pAMPK and increased phosphorylation of Rb at Ser804. However, when EGF and FGF were added to cells treated with the AMPK inhibitor Compound C, no increase in pAMPK or pRb was observed (). Thus, it appears that the failure of AMPK-directed phosphorylation of Rb in β1−/− NPCs, perhaps in response to endogenous growth factors, results in defects in G2M phase as well as the aberrant differentiation that leads to apoptosis.
AMPK is integrally involved in regulating cellular energy homeostasis and is activated by low cellular ATP levels, such as occurs by limiting oxygen or glucose supplies or exercise, conditions that enhance proliferative capacity of stem cells (
Burgers et al., 2008;
Fu et al., 2006;
Stolzing et al., 2006). To explore whether the proliferative effects of glucose restriction are manifested through activation of the AMPK-Rb axis, we monitored the growth of wildtype NPCs cultured in 2.5 mM to 25 mM (the amount present in Neurobasal medium) glucose for 48 hr. NPC cell numbers were increased when grown in low glucose medium, with 5 mM glucose giving the highest growth rate (). The NPC growth stimulation by low glucose was not observed in cells treated with Compound C, which severely inhibited neurosphere growth. Furthermore, no effect on growth by low glucose was observed in β1−/− NPCs, consistent with their lack of AMPK signaling (). Interestingly, there was a small but consistent increase in the phosphorylation of AMPK, Rb and ACC at lower glucose concentrations (). Remarkably, glucose limitation also reduced the proportion of Rb-bound E2F1, whereas Compound C treatment caused higher levels of Rb sequestration of E2F1 (). Collectively, our results demonstrate that perhaps growth factor signaling as well as other physiological/metabolic stimuli utilize the AMPK-Rb signaling pathway to modulate the growth and differentiation of neural stem and progenitor cells during mammalian brain development.